AN2 Therapeutics (ANTX) Cash from Investing Activities (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Cash from Investing Activities data on file, last reported at $8.3 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 9.82% year-over-year to $8.3 million in Q1 2026; TTM through Mar 2026 was $27.4 million, a 26.9% decrease from a year earlier, with the FY2025 full-year figure at $28.3 million, down 48.14% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $8.3 million, up from $7.2 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for ANTX reached as high as $26.3 million in Q1 2024 and fell as low as -$62.5 million in Q3 2023.
• Historically, Cash from Investing Activities has averaged $1.5 million across 5 years, with a median of $7.2 million in 2025.
• Across the five-year window, Cash from Investing Activities plunged 2595.81% in 2023 and surged 204.27% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $6.1 million in 2022, then sank by 93.06% to $420000.0 in 2023, then slumped by 1738.1% to -$6.9 million in 2024, then jumped by 204.27% to $7.2 million in 2025, then increased by 15.56% to $8.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $8.3 million in Q1 2026, $7.2 million in Q4 2025, and $6.1 million in Q3 2025.